Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)
Date:12/11/2008

inhaled short-acting beta2-agonists. Administered twice daily, SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in less than or
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
(Date:1/22/2015)... BETHESDA, Md. , Jan. 22, 2015 The Parenteral ... Manufacturing Science Program SM : Enabling Pharmaceutical Manufacturing,s Future. ... will fulfill the following goals: , Highlight the ... , Strengthen and build practical solutions by filling known gaps ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... Ameritox (SM), the nation,s leader in Pain Medication Monitoring ... Record for the Congressional hearing on "Costs of Prescription ... to medication monitoring as a potential solution to improving ... in lowering national healthcare costs. The hearing was held ...
... /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH ... manufacturer and marketer of orthopedic implants in China, today ... 2011 financial results on November 9, 2011, after the ... conference call and live webcast at 8:00 a.m. ET ...
Cached Medicine Technology:Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 2Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 3China Kanghui Holdings to Report Third Quarter 2011 Financial Results 2
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... Guide Now Available at Sunrise Communities and Online -MCLEAN, ... SRZ ) now offers a new informational guide ... affording senior care in today,s challenging economy. The ... , is available at Sunrise communities nationwide and also ...
... cancer patients, chemotherapy can be worse than cancer itself. ... -- or the tumor may mutate and stop responding to ... treatment and toxic side effects. , Now UCLA ... allow doctors to evaluate a tumor,s response to a drug ...
... what is believed to be a first-ever procedure, surgeons ... kidney through a small incision in the back of ... and transplanted into the donor,s niece, and both patients ... of the transplant division at Johns Hopkins University School ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Investor Conference on Monday, February 9, 2009 at 11:00 a.m. ... at the Waldorf-Astoria Hotel in New York. Steve Worland, ... an overview of Anadys and an update on its clinical ...
... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... simultaneous webcast on Tuesday, February 3, 2009 at 8:30 ... senior management team will provide an update on the ... Information To access the live call, please dial 800-299-7098 ...
... Machine Integration Server Enables Enterprises to Capture and Automate Faxes to ... ... Fla. (PRWEB) February 2, 2009 -- FaxBack® , the high-density ... announced the Fax Machine Integration Server , an easy-to-install plug-in ...
Cached Medicine News:Health News:Sunrise Senior Living Helps Families Explore Senior Care Financing Options with New Guide 2Health News:UCLA scientists develop crystal ball for personalized cancer treatment 2Health News:Hopkins transplant surgeons remove healthy kidney through donor's vagina 2Health News:Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference 2Health News:Rigel to Host Conference Call on February 3, 2009 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 2Health News:FaxBack Enables Fax Machine Integration With Document Management Systems 3
... has the highest g-force ever. But optimal ... force. Optima MAX combines maximum force, capacity, ... performance that's worlds apart from any other ... and enhanced efficiency, Optima takes productivity to ...
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
... L-XP ultracentrifuge is designed to play ... process if research involves proteomics, cytomics ... on-board computer, enhanced firmware, powerful Optima ... screen, Optima L-XP delivers superior functionality, ...
Medicine Products: